title: Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose.
abstract: BACKGROUND
  Although decennial adult boosters of tetanus and diphtheria toxoids are recommended in Canada and the United States, a second dose of pertussis vaccine is not currently recommended for adults.
  
  
  METHODS
  This open-label, postmarketing, multicenter study evaluated the tolerability and immunogenicity of a second dose of an adult formulation of tetanus, diphtheria, and pertussis vaccine (Tdap) in adolescents and adults 5 years after a first dose.
  
  
  RESULTS
  A total of 545 participants from previous Tdap vaccine studies, ranging in age from 15 to 69 years, participated in this study. Of these participants, 94.2% had at least one solicited adverse event after the booster dose such as injection-site erythema (28.6%), swelling (25.6%), or pain (87.6%) or a systemic adverse event such as myalgia (61.0%), headache (53.2%), malaise (38.2%), or fever (6.5%). These adverse events were slightly more frequent than after the initial dose. Postvaccination, 100% of participants had a tetanus antibody level ≥0.10IU/mL and 95% had a diphtheria antibody level ≥0.10IU/mL. For pertussis, 82.1% (pertussis toxoid), 96.7% (filamentous hemagglutinin), 95.6% (pertactin), and 99.8% (fimbriae) had a postvaccination antibody threshold of ≥50EU/mL.
  
  
  CONCLUSIONS
  A second dose of Tdap vaccine 5 years after the initial dose was well tolerated and immunogenic in adolescents and adults.
authors.affiliation: Canadian Center for Vaccinology, Dalhousie University, Halifax, NS, Canada. scott.halperin@dal.ca
authors.forename: Scott A
authors.initials: SA
authors.lastname: Halperin
authors.forename: Shelly
authors.initials: S
authors.lastname: McNeil
authors.forename: Joanne
authors.initials: J
authors.lastname: Langley
authors.forename: Mark
authors.initials: M
authors.lastname: Blatter
authors.forename: Marc
authors.initials: M
authors.lastname: Dionne
authors.forename: Joanne
authors.initials: J
authors.lastname: Embree
authors.forename: Roehl
authors.initials: R
authors.lastname: Johnson
authors.forename: Thomas
authors.initials: T
authors.lastname: Latiolais
authors.forename: William
authors.initials: W
authors.lastname: Meekison
authors.forename: Francisco
authors.initials: F
authors.lastname: Noya
authors.forename: Shelly
authors.initials: S
authors.lastname: Senders
authors.forename: Paul
authors.initials: P
authors.lastname: Zickler
authors.forename: David R
authors.initials: DR
authors.lastname: Johnson
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000907:Antibodies, Bacterial / Q000097:blood*; D000992:Antitoxins / Q000097:blood*; D002170:Canada; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D004890:Erythema / Q000139:chemically induced / Q000453:epidemiology; D005221:Fatigue / Q000139:chemically induced / Q000453:epidemiology; D005260:Female; D005334:Fever / Q000139:chemically induced / Q000453:epidemiology; D006261:Headache / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D007117:Immunization, Secondary / Q000009:adverse effects* / Q000379:methods*; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000139:chemically induced / Q000453:epidemiology; D014481:United States; D055815:Young Adult
chemical_list: D000907:Antibodies, Bacterial; D000992:Antitoxins; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines